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Abstract
Triple-negative breast cancer (TNBC) is defined as a molecular subtype of 
breast cancer that lacks expression of hormone receptors (oestrogen and progester-
one receptor) and HER2/neu/ErbB2 protein. It accounts for 15–20% of all invasive 
breast cancers. The occurrence of TNBC is often associated with younger age at 
the time of diagnosis and pre-menopausal status, early onset of menarche, higher 
body mass index (BMI) in the pre-menopausal period, race and ethnicity (African, 
Hispanic) and the presence of germline mutation in the BRCA1/2 genes or somatic 
mutation in the TP53 or PTEN genes. TNBCs are specific in its aggressive biological 
behaviour, shorter interval to disease progression and more frequent relapse within 
five years (19 to 40 months). The most of TNBCs are represented by high-grade 
invasive carcinomas of no special type (NST) with high proliferation index mea-
sured by Ki-67 nuclear expression, followed by metaplastic carcinomas, secretory 
carcinomas, and adenoid cystic carcinomas. Genetical and morphological hetero-
geneity inside TNBC is responsible for the higher frequency of primary and second-
ary resistance to systemic therapy. The scope of this chapter is to summarise the 
potential therapeutic agents involved in regulation of cell proliferation, migration, 
angiogenesis, apoptosis, gene expression and DNA damage or immune response. 
The insight into this issue is essential for the setting of the optimal chemotherapy 
regimen and targeted therapeutic strategy.
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1. Introduction
Triple - negative breast cancer (TNBC) represents a morphologically and geneti-
cally heterogeneous molecular subtype of breast cancer lacking the expression of 
hormone receptors (oestrogen and progesterone receptor) and HER2/neu/ErbB2 
protein. It accounts for 15–20% of all cases [1]. The occurrence of TNBC is often 
associated with younger age at the time of diagnosis and pre-menopausal status, 
early onset of menarche, higher body mass index (BMI) in the pre-menopausal 
period, race and ethnicity (African, Hispanic) and the presence of germline muta-
tion in the BRCA1/2 genes or somatic mutation in the TP53 or PTEN genes [2, 3]. In 
addition, for BRCA1/2 mutant gene carriers, the risk of developing TNBC multiplies 
after therapeutic exposure to ionising radiation. Other genetic alterations include 
mutations in the RB1, NF1, ERBB3, ERBB4, ALK and EGFR genes, changes in the 
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NOTCH1/2, MAST1/2 gene copy number or MAGI3 - AKT3 gene fusion. The gain 
on chromosomes 1q, 8q, 10q and the loss on chromosomes 5q and 8p were also 
demonstrated.
From a clinical point of view, TNBC is specific in its aggressive biological 
behaviour, shorter interval to disease progression and more frequent relapse within 
five years (19 to 40 months vs. 35 to 65 months) [4]. The median overall survival 
(OS) for metastatic TNBC is reported to be 9 to 12 months [5]. Due to these tumour 
characteristics, chemotherapy is often indicated already during the initial phase 
of treatment. Heterogeneity inside TNBC is responsible for the higher frequency 
of primary and secondary resistance to treatment [6]. The current research trends 
therefore focus on finding the new potentially therapeutically manageable mole-
cules, which could significantly help to decrease the risk of metastasis development 
and disease recurrence.
Compared to other molecular subtypes, TNBCs differ in their high degree of 
gene instability. Based on the gene expression profiling, TNBC can be subclassified 
into several distinct molecular subtypes. Lehmann et al. represent one of the first 
research groups using this approach in practical diagnostics [7, 8]. Since then, a 
couple of classification schemes have been introduced; see Table 1 [9–13].
The essential clue for effective breast cancer management is comprehensive 
evaluation of number of prognostic and predictive molecular indicators. While 




Ma et al. [9] BL Increased CK5/6, EGFR expression




Decreased claudin 3, 4, 7 expression
Lehmann et al. [7] BL1 Increased Ki-67 expression
BL2 Increased CD10, p63 expression
LAR Increased AR expression
Aberrant FOXA1, KRT18, XBP1 gene activation
M Aberrant regulation of Wnt, ALK, TGF-β
MSL Aberrant regulation of Rho, ALK, TGF-β, Wnt/β-catenin, ERK1/2, 
EGFR, PDGF, PI3K
IM Aberrant regulation of NFKB, TNF, JAK/STAT
Burstein et al. [10] LAR Increased AR, MUC1 expression
Aberrant PIK3CA, AKT1, CDH1 gene activation
M Increased PDGF-A, c-Kit expression
BLIA Aberrant regulation of STAT
Presence of B /T/NK immune cells
BLIS Aberrant regulation of VTCN1
Jézéquel et al. [11] BL Immune cells -, TAM – like cells +
LAR Increased AR expression
Aberrant FOXA1, KRT18, XBP1 gene activation
“BL 
- enriched”
Immune cells +, TAM – like cells -
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information on the response to a specific therapy. The all prognostic clinicopatho-
logical characteristics such as patient age at the time of diagnosis, clinical and 
pathological tumour stage, tumour type with detailed tumour morphology analysis 
including the intensity of tumour infiltrating lymphocytes (TILs), tumour grade, 
occurrence and extent of in situ carcinoma and family history of breast cancer 
should be taken into account.
The most of TNBCs are represented by high-grade invasive carcinomas of 
no special type (NST) with high proliferation index measured by Ki-67 nuclear 
expression, followed by metaplastic carcinomas, secretory carcinomas, and adenoid 
cystic carcinomas [14]. The morphological pattern of invasive carcinomas NST 
may involve medullary, lipid-rich, apocrine, pleomorphic or spindle cell areas. 
Carcinomas with spindle tumour cell transformation are usually related to “claudin-
low” molecular subtype (CD44+/ D24−/low) and epithelial to mesenchymal transi-
tion (EMT) process [15–17]. Metaplastic breast cancers and secretory carcinomas 
account for 0.2 to 5%, respectively 0.02% of all breast cancers [14]. Adenoid-cystic 
carcinomas with typical fusion of the MYB - NFIB genes and mutations in the 
EP300, NOTCH1, ER882 and FGFR1 genes are described in 0.1 to 3.5% of breast 
tumours [14].
2. Molecular prognostic and predictive markers
Individual molecules involved in the process of TNBC carcinogenesis may be 
divided into several groups. The groups of proteins include proteins participating in 
mechanisms of repair of damaged DNA; proteins responsible for regulation of cell 
proliferation, migration, angiogenesis, programmed – cell death (apoptosis) and 
immune response (immune checkpoint proteins; and groups of proteins modifying 
gene expression (see Table 2).
2.1 Regulators in the DNA damage response
Genes and proteins involved in the repair of damaged DNA (poly (ADP-ribose) 
polymerase, genes with tumour suppressor function PTEN, BRCA 1, BRCA2, TP53 




Ahn et al. [12] BL Aberrant ATR, BRCA1/2, etc. gene activation
M PIK3CA gene mutation, PTEN gene inactivation
Aberrant regulation of PI3K / AKT
IM Aberrant regulation of NFKB, TNF, JAK/STAT, VTCN1, presence 
of B/T/NK immune cells
LAR Increased AR expression
Aberrant FOXA1, KRT18, XBP1 gene activation
Zeng et al. [13] BL Increased CK5/6, EGFR expression
NBL Absence of CK5/6, EGFR expression
BL = basal – like; BL1/2 = basal – like 1/2; LAR = luminal androgen receptor; M = mesenchymal; 
MSL = mesenchymal stem – like; IM = immunomodulatory; BLIA = basal-like immune-activated;  
BLIS = basal-like immune-suppressed; NBL = normal breast - like.
Table 1. 
History of proposed TNBC classification systems.
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proceeds correctly. Deoxyribonucleic acid (DNA) may be damaged due to physical, 
chemical, as well as biological processes. Repair of the damaged DNA is realised 
by several mechanisms, including repair of mismatched bases (mismatch repair - 
MMR), nucleotide and base excision repair (nucleotide excision repair“- NER; 
„base excision repair“- BER) or repair of double-strand DNA breaks by homologous 
recombination (HR) or by non-homologous end joining NHEJ).
The enzyme family poly (ADP-ribose) polymerase is responsible for the trans-
fer of the subunit (ADP) – ribose from NAD+ to the acceptor protein creating long, 
branched and negatively charged polymers of poly - ADP ribose (Figure 1) [18–22]. 
PARP-1 is the most abundant, an evolutionally highly conserved enzyme involved 
in the repair of damaged DNA through BER. It is composed of an NH2-terminal 
domain with three „Zinc fingers“, which binds to the damaged DNA, automodi-
fication domains and C-terminal catalytic domains. The conformation change 
arising from the binding of PARP to the site of damaged DNA enables catalysis 
of the transfer of ADP-ribose from NAD+ to its own molecule and histone H1. 
Figure 1. 
Mechanism of action of PARP inhibitors (Koleckova M, www.biorender.com). Efficient single-strand breaks 
(SSB) repair provided by PARP is essential for the cell survival. The mechanism of action of PARP inhibitors 
include the suppression of this base excision repair (BER) – mediated pathway, resulting in the pathologic 
double-strand breaks (DSB) with homologous recombination (HR) – mediated repair and thus genome 
stability and the cell death.
Regulators in the DNA damage response BRCA1, BRCA2, PARP, PTEN, pRb, p53
Regulators of cell migration and proliferation EGFR, VEGFR, FGFR
Regulators of apoptosis Fas, TRAIL, p53, Bcl-2
Regulators of gene expression microRNA, lncRNA, circRNA, siRNA
Steroid receptors Androgen receptor
Immune checkpoint proteins PD - 1, PD - L1
Table 2. 
Classification of molecular prognostic and predictive markers.
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Subsequently, degradation of the chromatin structure occurs and there is an influx 
of additional damaged DNA repair proteins (for example DNA ligase 3, DNA poly-
merase β and protein XRCC1). In patients with TNBC with a confirmed mutation 
in the gene BRCA1 or BRCA2, PARP takes over a backup function, it inactivates the 
degradation of caspases and initiates apoptosis utilising so-called synthetic lethal-
ity. The direct inhibitory effect on the PI3K/AKT/mTOR and Wnt/β-catenin signal-
ling pathways has also been established, with corresponding changes in miRNA and 
serine/threonine kinase ATM expression. PARP inhibitors may be administered in 
monotherapy as well as in combination. They amplify the effect of the administered 
chemotherapy and/or inhibitors of molecules of the signalling pathway PI3K/AKT/
mTOR, inhibitors of deacetylation of histones, CDK1, EGFR, AR, ATM or MYC. 
In cases treated by olaparib versus the chemotherapy group (capecitabin, eribulin 
or vinorelbin based on selection of the examining physician), the progression-free 
survival (PFS) was prolonged from 4.2 months to 7 months. A higher rate of thera-
peutic response was also discovered (59.9%). A positive finding was also observed 
with talazoparib in monotherapy, where PFS was prolonged from 5.6 months to 
8.6 months, while increasing the rate of therapeutic response to 62.6%. Finally, 
administration of veliparib in combination with paclitaxel and carboplatin seems to 
be effective. Mechanisms leading to the development of resistance to PARP inhibi-
tors include secondary mutations in the BRCA1 and BRCA2 genes, in genes coding 
the P-glycoprotein pump or the loss of protein 1 binding protein p53 (53BP1).
Tumour suppressor gene PTEN participates in the regulation of cell prolifera-
tion, migration and apoptosis under physiological conditions [23–26]. Phosphatase 
and tensin homologue (PTEN) represent a protein belonging to the tyrosine-
phosphatase family with phosphatidyl-inositol-phosphatase activity. After binding 
tensin, a focal adhesion complex is created, which affects cell integrity and the 
transfer of intercellular as well as intracellular signals. The catalytic domain C2 is 
responsible for PTEN binding to the cell’s phospholipid membrane and ensures 
Ca2+ dependent membrane transport of signal proteins. The resulting action of 
protein PTEN is the inhibition of proteins of the signalling pathway PI3K/Akt/
mTOR (Figure 2), whose aberrant activation via activation of genes PI3CA, AKT1 
and MTOR would lead to induction of the process of cancerogenesis. Indirect acti-
vation of protein PTEN is realised by the fully functional gene TP53 (wild – type 
p53 protein). Alteration in the expression of gene PTEN is a result of its deletion 
or inactivating mutation. It occurs in up to 41% of cases of TNBC and correlates 
with a shorter PFS and overall survival (OS). Therapeutic inhibition of aberrantly 
activated PI3K/Akt/mTOR of the signalling pathway is possible by administering 
paclitaxel in combination with ATK inhibitor ipatasertib. Compared with placebo, 
ipatasertib led to a significant prolonging of PFS - from 4.9 months to 9 months, 
as well as OS – from 18.4 months to 23.1 months). Similarly, effective, but with a 
greater number of side effects, was the combination of paclitaxel with capivasertib 
(PFS – 5.9 months; OS – 19.1 months).
Tumour suppressor genes BRCA1 and BRCA2 are involved in the regulatory 
phases S and G2 of the cell cycle [27–29]. As transcription factors, they participate 
in the repair mechanism of DNA single-strand breaks via HR. In cases of DNA 
double-strand breaks, phosphorylation of protein BRCA1 by protein kinase ATM 
takes place, with subsequent interaction with protein RAD51, transported with 
the help of protein BRCA2, and leads to repair of the damaged DNA. In case there 
is a loss of function of genes BRCA1 and BRCA2, the PARP genes take over their 
role, inactivates caspase degradation and initiates apoptosis through mechanism of 
synthetic lethality. Inactivating mutations in the BRCA1 gene were determined in 
40% of cases of familial breast cancer. Autosomal dominant inheritance was found 
in 5–10% of patients. Confirmation of a germline mutation in the BRCA1 gene is 
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considered to be an unfavourable prognostic marker. However, in NBC it predicts 
an increased therapeutic response to anthracyclines, taxanes, platinum derivatives, 
and in advanced disease stages, PARP inhibitors.
Protein Rb (pRb), a product of tumour suppressor gene RB1, inhibits the 
bound transcription factor E2F and thus is significant in regulating the cell cycle, 
chromatin structure, proliferation and differentiation of tumour cells and cell death 
[30, 31]. Lost expression of the gene RB1 plays a role in the pathogenesis of tumour 
development. This is due to inactivation of deletion alleles, point mutation or 
hypermethylation of its promoter, increased expression and/or amplification of the 
gene for cyclin D1, decreased expression of inhibitor p16INK4A or binding protein 
pRb by oncoprotein E7 HPV. In addition, the concurrent presence of the mutation 
in genes RB1 and TP53 induces the process of epithelial-mesenchymal transition 
(EMT). In TNBC with confirmed inactivation of the RB1 gene, this leads to induc-
tion of increased sensitivity to radiotherapy and cytotoxic drugs, such as doxorubi-
cin, methotrexate or inhibitor of mitochondrial translation of proteins, tigecyclin. 
Inhibition of expression of glucose 1 transporter (GLUT1) by tumour cells with 
confirmed mutation of the RB1 gene presents a new promising therapeutic goal.
2.2 Regulators of cell proliferation, migration and angiogenesis
The loss of effective mechanisms to repair damaged DNA during the cell cycle 
leads to uncontrolled cell division and their tumour transformation. Adequate 
nutrition for the tumour cells is provided by the process of angiogenesis. To initi-
ate the metastatic cascade, there must be an increased expression of proteases by 
tumour cells with subsequent degradation of the basal membrane. Cells of the 
tumour stroma may amplify the aggressive potential of the tumour even further 
and thus participate in the EMT process.
Figure 2. 
Mechanism of action of PTEN protein (Koleckova M, www.biorender.com). PTEN protein (Phosphatase 
and tensin homologue) is essential for the regulation of intracellular levels of phosphorylation, cell migration, 
proliferation and survival. It plays a pivotal role in the phosphatidyl-inositol-3-kinase (PI3-K) pathway 
involved in the inhibition of proteins of the signalling pathway PI3K/Akt/mTOR. Inactivation of the PTEN 
tumour suppressor gene leads to the aberrant activation of PI3CA, Akt and mTORC1 genes associated with the 
initiation of the process of cancerogenesis.
7
Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer
DOI: http://dx.doi.org/10.5772/intechopen.97282
Fibroblast growth factor receptor (FGFR) consists of an extracellular domain, 
transmembrane domain and an intracellular domain with tyrosine kinase activity 
[32–34]. The binding of fibroblast growth factor and its cofactor to the extracellular 
portion of one of four evolutionally conserved receptors leads to the dimeriza-
tion of its polypeptide chain, autophosphorylation and subsequent activation of 
signalling molecules, which influence cell proliferation and differentiation (MAPK, 
PI3K-AKT), inflammatory reaction (MAPK – kinase p38, JNK), angiogenesis 
(MAPK - kinase p38; PI3K-AKT - FOXO1, TSC2), apoptosis (MAPK – JNK; PI3K-
AKT - FOXO1, TSC2) and cell growth, metabolism and motility (PLCγ – IP3 – DAG, 
PKC). The therapeutic response to the administered FGFR inhibitors (for example 
dovitinib, lucitanib) differs greatly. While in cases of confirmed fusion of the genes 
FGFR3-TACC3 or amplification of the gene for FGFR1, an excellent therapeutic 
response is observed, the mutation in specific genes is associated with a signifi-
cantly reduced to zero therapeutic response. In breast cancer, the aberrant activa-
tion of receptors FGFR1 and FGFR4 is associated with resistance to chemotherapy 
(doxorubicin, cyclophosphamide), endocrine therapy (tamoxifen, fulvestrant) and 
VEGF inhibitors (bevacizumab).
Epidermal growth factor receptor (EGFR) consists of a glycoprotein with 
an extracellular domain for ligand binding (EGF and TNF-α), a transmembrane 
domain and cytoplasmic domain with tyrosine kinase activity [35–37]. The EGFR/
ErbB1 receptor is significantly involved in the regulation of the cell cycle, cell 
migration, proliferation, differentiation and survival, by way of activating its 
secondary signalling pathways Ras/Raf/MEK/ERK, Ras/PI3K/AKT1/mTOR or Src/
STAT3. After translocation to the nucleus, EGFR/ErbB1 regulates transcription and 
repair of damaged DNA. Aberrant activation and increased expression of EGFR/
ErbB1 is caused by amplification or mutation of its gene. Increased expression of 
EGFR was proven in 13–76% of TNBC, whereas amplification of the gene in only 
2–24% of cases and is more frequent in patients with mutation in the BRCA1 gene. 
An increased number of copies of the EGFR gene was found in 8–27% TNBC. The 
use of EGFR inhibitors in monotherapy or in combination with chemotherapy 
is being considered especially in advanced and generalised forms of TNBC. The 
combination of docetaxel with cetuximab seems to be effective. In patients treated 
with a combination of cisplatin and cetuximab, a correlation between therapeutic 
response and intensity of CD8+ lymphocyte infiltration (tumour infiltrating lym-
phocytes – TILs) has been reported. Combination therapy with PARP inhibitors or 
immune checkpoint inhibitors (PD-1/PD-L1) has promising therapeutic potential. 
The synergistic effect of anti – EGFR therapy was also noted with radiation therapy. 
A possible mechanism of resistance development to EGFR inhibitors is methyla-
tion of the extracellular domain of the EGFR/ErB1 receptor by protein PRMT1 or 
increased expression of the Notch3 protein.
Vascular endothelial growth factor (VEGF) binds to its specific trans-
membrane receptors with tyrosine kinase activity (VEGFR-1 and VEGFR-2) by 
activating matrix metalloproteinases (MMP) and stimulates cell migration and 
endothelium proliferation with the creation of vascular lumen and fenestrations 
[38, 39]. Unregulated angiogenesis may be induced by genetic changes (muta-
tions in tumour suppressor genes TP53 or VHL, activation of oncogenes), as well 
as metabolic changes (hypoxia, effect of gonadal hormones, growth factors and 
cytokines). Increased VEGF expression is often observed in patients with advanced 
disease stages, resistant to therapy or with a mutation in the BRCA1/2 genes. In 
TNBC, a synergic anti – angiogenic effect of the intravenously administered AAV2-
VEGF-Trap and paclitaxel has been detected. Coenzyme Q0 has a similar effect, 
whereby its effect on signalling pathway PI3K/AKT/NFKB/MMP-9 and negative 
regulation of MMP-2/− 9, urokinase activator of plasminogen (uPA), receptors 
Breast Cancer
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uPAR and VEGF lead to induction of apoptosis and inhibition of EMT. In advanced 
and metastasizing forms of TNBC, the benefits of combination therapy of bevaci-
zumab and chemotherapy or mTOR inhibitors (temsirolimus, everolimus) or EGFR 
(erlotinib) are also being considered.
2.3 Proteins regulating apoptosis
Cell death receptors Fas and TRAIL of the tumour necrotizing factor (TNF) 
family are considered to be potential anti-tumour molecules. The Fas receptor 
(CD95R) is a transmembrane protein, composed of an extracellular, transmem-
brane and intracellular domain [40]. Binding the soluble membrane ligand of 
cytotoxic T-lymphocytes CD95 (CD95L, FasL) leads to the creation of complex 
DISC and activates the extrinsic apoptosis pathway. Soluble ligand CD95L, labelled 
cl-CD95L, is responsible for activating the immune response, EGFR and the 
oncogenic signalling pathway c-yes/Ca2+/PI3K. Increased expression of CD95R was 
found in almost 49% of TNBC. Decreased expression of the Fas receptor (CD95R) 
is a marker of poor prognosis. Expression of CD95L by tumour blood vessels and 
detection of serum levels of cl-CD95L predicts metastatic potential of the tumour 
in patients with TNBC. Excessive expression of protein Lifeguard by TNBC tumour 
cells inhibits the activity of CD95R receptor and thus presents a possible mecha-
nism of resistance to systemic therapy with cisplatin. The TRAIL receptor ligand 
(Apo2L) activates the extrinsic apoptosis pathway in the mesenchymal subtype 
of TNBC [41]. Agonists of the TRAIL (TNF - related apoptosis -inducing ligand) 
receptor stimulate death receptors DR4 and/or DR5. In advanced and metastasizing 
forms of TNBC, molecule MEDI3039 has shown a positive therapeutic effect.
Gene TP53 with tumour suppressor function plays the role of genome guard-
ian. Its product, protein p53, acts as a transcription factor following translocation 
to the nucleus and has a fundamental influence on the regulation of checkpoints 
of the cell cycle, cellular response to damaged DNA and telomeres, aerobic cell 
metabolism, apoptosis, inhibition of angiogenesis and oncogene activation [42]. 
Protein p53 consists of an N – terminal domain activating transcription, DNA 
binding domain, oligomerization domain and protease-sensitive domain, which 
enables the binding of p53 to damaged DNA. Functional protein p53 exists in the 
form of a tetramer, where loss of function of one subunit causes nonfunction of 
the entire complex. Mutations in the TP53 gene were discovered in 60–88% of 
TNBC. They are considered as a negative prognostic and predictive marker in terms 
of disease-free survival (DFS), overall survival (OS) and therapeutic response to 
chemotherapy. Manipulating genes involved in the regulation of protein p53 and 
its isoforms (Cyclin G2, Sharp-1, PI3K/AKT/mTOR, Chk1, CDK, Hsp90, Mdm2, 
histone deacetylase) may lead to new therapeutic strategies for TNBC.
Anti-apoptotic protein Bcl-2 is reported to be an independent negative prog-
nostic marker of survival in patients with TNBC [43–45]. Expression of protein 
Bcl-2 in TNBC positively correlates with the size of the tumour and the develop-
ment of metastases to regional axillary lymph nodes. It is also associated with a 
lower sensitivity to neoadjuvant and adjuvant chemotherapy with anthracyclines 
and resistance of the tumour to radiation therapy due to activation of the STAT3 
gene. The use of Bcl-2 inhibitors may have a protective effect against resistance 
development to chemotherapy and immunotherapy.
2.4 Regulation of gene expression
Detection of epigenetic changes taking place in breast cancer may aid in determin-
ing disease prognosis and in predicting the response to treatment. These primarily 
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include changes in DNA methylation, modification of histones and altering miRNA 
expression [46–53]. Recently, the regulatory role of lncRNA, circRNA and siRNA has 
been described.
DNA methylation is among the most important modifications, ensured by 
the action of DNA methyltranferases, regulated by genes DNMT1, DNMT3a and 
especially DNMT3b. Also associated with the development and progression of 
breast cancer is hypermethylation of CpG promoters of tumour suppressor genes 
(RASSF1A, CDKN2A, CDKN1B, CCND2a), genes regulating repair of damaged 
DNA (BRCA1, MLH1, MGMT), cellular detoxification genes (GSTP1), adhesion, 
invasion (TWIST1, CDH1, TIMP3), hormone receptors (ER, PR) and apoptosis 
(HOXA5, TMS1).
Post-translational modification of histones includes their phosphorylation, 
ubiquitination, methylation and demythylation, acetylation and deacetylation. 
Methylation of histone H3K27 by protein EZH2 is described in aggressive and 
metastasizing forms of breast cancer. A therapeutic response may be reached using 
histone deacetylase inhibitors (vorinostat, entinostat and panobinostat) in mono-
therapy or in combination with cytotoxic, hormonal or targeted anti - HER2 and 
anti - VEGF therapy.
MiRNA represent endogenous short non-coding single strand RNA molecules 
with a length of 18 to 25 nucleotides. The miRNA sequence is phylogenetically 
conserved. They are partially or completely complementary to one or more media-
tor RNA (mRNA) and may also regulate other miRNAs. MiRNAs are significant 
regulators of gene expression and participate in the regulation of more than 50% 
of human genes. They are involved in angiogenesis, cell growth, proliferation, 
differentiation, effectiveness of mechanisms of damaged DNA repair and apopto-
sis. Changes in miRNA expression are therefore responsible for the development 
of many diseases, including dysfunctions of the immune system, tumours or 
resistance to pharmacological or radiation therapy. Depending on their role in the 
pathogenesis of tumour development, they can be divided into two types, miRNA 
with oncogenic or with tumour suppressor function. The positive influence on 
the EMT process also potentiates tumour metastasis. In the past years, miRNA has 
received much attention in connection with changes in its serum concentrations and 
its possible prognostic and predictive potential.
The miRNA biosynthesis is predominantly enabled by two major pathways - 
canonical and non-canonical pathway. The first pathway is initiated by the genera-
tion of the pri-miRNA transcript which is cleaved by microprocessor complex 
(Drosha and DGCR8) into precursor-miRNA (pre-miRNA). Pre-miRNA is trans-
ferred by the Exportin5/RanGTP to the cytoplasm and processed by the RNase III 
endonuclease Dicer to produce the mature miRNA duplex. The load of 5p or 3p 
strands of the mature miRNA duplex into the Argonaute (AGO) family of proteins 
to form a miRNA-induced silencing complex (miRISC). The second pathway begins 
by microprocessor complex – mediated cleavage of small hairpin RNA (shRNA) 
with following its export to the cytoplasm via Exportin5/RanGTP. Nevertheless, 
the further possible pathways were identified (e.g. Dicer-independent cleavage, 
miirtrons and 7-methylguanine capped (m7G)-pre-miRNA formation).
Long non-coding RNA (lncRNA) are, contrarily, molecules with a length 
of 200 and more nucleotides. Aberrantly increased lncRNA expression is able 
to stimulate the oncogenic signalling pathway PI3K/AKT, as well as changes in 
miRNA expression. They participate in the regulation of the biological behaviour of 
tumours and may induce a therapeutic response to administered systemic therapy. 
Newly described lncRNA includes DANCR (lncRNA - differentiation antagonis-
ing non-protein coding RNA), sONE, CCAT1 or GAS5. So-called circular RNA 
( circRNA) has a similar significance.
Breast Cancer
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Short interfering RNA molecules of siRNA are due to their ability to reduce the 
expression of protein Bcl-2 and p-glycoprotein considered to be one of the possible 
mechanisms for developing resistance to chemotherapy in TNBC. Formation of 
conjugates with nanoparticles of silicon dioxide, or in combination with chemo-
therapy, may enhance therapeutic possibilities in the future.
2.5 Steroid androgen receptor
The androgen receptor (AR) is a nuclear steroid hormone receptor which is 
expressed in 70–90% of all breast cancers [54–56]. It contains a transactivation 
N-terminal domain, a DNA-binding domain and a C-terminal domain. The func-
tion of AR as a transcription factor is to modulate the activity of steroid-regulated 
genes, or to alter post-transcription processes, which leads to changes in levels of 
specific mRNA and proteins. Inactive form of AR is kept in the cytoplasm by a het-
erocomplex with heat-shock proteins and a chaperone complex (HSP-70, HSP-90). 
There exist two mechanisms of AR activation – genomic modality and non-genomic 
modality. Genomic modality is implemented by androgen binding to the C-terminal 
domain of AR, its conformational change, dimerization and translocation into the 
nucleus, leading to a promotion of a co-activator-mediated transcription of target 
genes. Non – genomic modality activates AR through ERK dependent (interaction 
with PI3K, Src proteins, Ras GTPase) or ERK independent signal transduction 
(mTOR phosphorylation, FOXO1 inactivation, PKA activation)
In TNBC, increased expression of AR was observed in 10–50% of cases. 
Although several studies concerning ER-related breast cancers confirm a positive 
correlation between its increased expression and disease-free survival (DFS) as 
well as overall survival (OS), others claim the opposite. Expression of AR in TNBC 
is associated with lower grade, lower proliferation activity and lower disease stage. 
The lack of AR expression is thus considered to be a factor associated with a higher 
risk of disease recurrence and development of distant tumour metastases. Taking 
into account the sensitivity of the tumour to systemic therapy, the use of AR 
antagonists in clinical practice seems more than promising.
2.6 Immune checkpoint proteins
Physiologically, healthy tissue is protected from damage by its own immu-
nocompetent cells by inducing immune tolerance. It is mediated by cells of the 
immune system (especially T – lymphocytes, B - lymphocytes, macrophages, 
dendritic cells), which are able to effectively detect tumour antigens and activate 
a cellular and humoral antitumour response. A more intense antitumour immune 
response correlates with longer overall patient survival, period without develop-
ment of metastases, period without disease relapse and symptom-free interval.
Understanding the mechanism of how tumour cells escape from immune 
supervision (theory of immunosurveillance) led to the identification of immune 
checkpoint proteins as potential aims of immunotherapy. The signalling pathway 
PD1/PD-L1 under normal conditions inhibits the PI3K/Akt and MAP-kinase 
pathway (Ras/MEK/Er) and leads to the induction of apoptosis and termination of 
the cell cycle. It also limits the effector function of CD8+ T-lymphocytes in favour 
of regulatory CD4+ T-lymphocytes. Receptor protein PD-1 is encoded by the gene 
PDCD1 on chromosome 2. Its role in the immune system is played by two ligands 
with co-inhibitive function, protein PD-L1 (CD274) and PD-L2 (CD273). PD-L1 is 
expressed on the surface of T - and B - lymphocytes, dendritic cells, macrophages, 
mesenchymal stem cells and mastocytes; PD-L2 is only expressed on the surface of 
antigen-presenting cells and mastocytes.
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The testing of monoclonal antibodies with anti-PD-L1 inhibitory effect and their 
introduction into clinical practice signified a breakthrough in the treatment of a 
number of tumours [57–65]. Increased expression of PD-L1 in tumour cells is gener-
ally associated with poor disease prognosis. Contrarily, its increased expression by 
immune system cells (TILs) prolongs overall patient survival. Increased expres-
sion was observed in 20% of TNBC cases. Expression of PD – L1 in the tumour 
and its metastases in the lymph nodes is very heterogeneous and changes in time. 
Administration of immune checkpoint inhibitors (anti – PD1 - pembrolizumab, 
anti – PD-L1 - atezolizumab) with cytotoxic drugs is recommended in advanced 
forms of TNBC. Atezolizumab in combination with nab – paclitaxel has been shown 
to be effective; cases with increased expression of PD-L1 reported a prolongation of 
progression-free survival (PFS) from 5 months to 7.5 months and overall survival 
(OS) from 15.5 months to 25 months. Complete pathological response (pCR) was 
reached in 51.9% of cases receiving atezolizumab with nab – paclitaxel and carbo-
platin, and in 64.8% of cases receiving pembrolizumab with nab – paclitaxel and 
carboplatin (Figure 3).
3. Conclusions and future perspectives
The issue of TNBC is still a challenge for many investigators over the world. 
The current scientific interest is mainly focused on the development of promis-
ing therapeutic targets. Due to poor prognosis associated with tumour aggressive 
Figure 3. 
Immune response to cancer - mechanism of action of PD-1/PD-L1 (Koleckova M, www.biorender.com). The 
mechanism of PD-1/PD-L1 axis action is based on the controlling of the anti-tumour immune response by the 
self-tolerance promotion. The activity of PD-1 and its ligand (PD-L1, PD-L2) is involved in the modulation of 
immune system accompanied by T cell activation, proliferation, cytotoxic secretion and apoptosis. Targeting the 
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biological behaviour, high rates of metastases and unpredictable response to the 
primary systemic chemotherapy and radiotherapy, the detailed analysis of the 
mechanisms of TNBC genesis is asked. Identification of new potential targets and 
the development of specific targeted therapy is pivotal for improvement of the 
existing clinical outcomes. The knowledge of the crucial participation of immune 
system in carcinogenesis significantly extended the range of therapeutic options. 
Ongoing clinical trials testing different types of molecules may pave the way for 
effective pharmacological synergy and better treatment results.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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